We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Beovu

News List

NICE recommends Beovu (brolucizumab) for treatment of wet AMD europeanpharmaceuticalreview
February 07, 2021
NICE has issued final guidance recommending Beovu (brolucizumab) to treat wet age-related macular degeneration in adults.
NICE recommends Novartis’ wet AMD drug Beovu pharmatimes
December 16, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet age-related degeneration (AMD) patients.
Novartis Reports Positive Topline Results from Beovu for Diabetic Macular Edema americanpharmaceuticalreview
September 21, 2020
Novartis reported the first interpretable results of the Phase III KITE study, assessing the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME).
Novartis launches review of Beovu after safety concerns, says report europeanpharmaceuticalreview
March 04, 2020
An external review of the medicine Beovu has been announced by Novartis, which produces the drug, according to a new report.
EMA recommends five drugs for approval after December meeting europeanpharmaceuticalreview
December 17, 2019
The EMA’s CHMP has adopted a positive opinion for five medicines and recommended extending the indications for eight more.